FibroGen to Report Third Quarter 2024 Financial Results
FibroGen (NASDAQ: FGEN) has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, after market close. The company will host a conference call at 5:00 PM Eastern Time to discuss corporate and financial performance with the investment community. The call will be accessible via toll-free number 1-877-300-8521 for domestic callers and 1-412-317-6026 for international investors. A webcast replay will be available on FibroGen's website investor section.
FibroGen (NASDAQ: FGEN) ha programmato l'annuncio dei suoi risultati finanziari del terzo trimestre 2024 per martedì 12 novembre, dopo la chiusura del mercato. L'azienda organizzerà una conferenza telefonica alle 17:00 ora orientale per discutere le prestazioni aziendali e finanziarie con la comunità degli investitori. La chiamata sarà accessibile tramite il numero verde 1-877-300-8521 per i chiamanti nazionali e 1-412-317-6026 per gli investitori internazionali. Una registrazione della web conference sarà disponibile nella sezione investitori del sito web di FibroGen.
FibroGen (NASDAQ: FGEN) ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el martes 12 de noviembre, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica a las 5:00 PM, hora del Este, para discutir el rendimiento corporativo y financiero con la comunidad de inversores. La llamada será accesible a través del número gratuito 1-877-300-8521 para los llamantes nacionales y 1-412-317-6026 para los inversores internacionales. Una repetición de la transmisión web estará disponible en la sección de inversores del sitio web de FibroGen.
FibroGen (NASDAQ: FGEN)은 2024년 3분기 재무 결과 발표를 11월 12일 화요일, 시장 마감 후로 예정하고 있습니다. 회사는 투자자 커뮤니티와 함께 기업 및 재무 성과를 논의하기 위해 동부 표준시 기준 오후 5:00에 컨퍼런스 콜을 개최할 예정입니다. 국내 통화자는 무료 번호 1-877-300-8521로, 국제 투자자는 1-412-317-6026으로 접근할 수 있습니다. FibroGen의 웹 사이트 투자자 섹션에서는 웹캐스트 재생이 가능합니다.
FibroGen (NASDAQ: FGEN) a prévu l'annonce de ses résultats financiers du troisième trimestre 2024 pour le mardi 12 novembre, après la fermeture du marché. L'entreprise organisera une conférence téléphonique à 17h00, heure de l'Est, pour discuter de sa performance d'entreprise et financière avec la communauté des investisseurs. L'appel sera accessible via le numéro sans frais 1-877-300-8521 pour les appelants nationaux et 1-412-317-6026 pour les investisseurs internationaux. Un enregistrement de la webconférence sera disponible dans la section investisseurs du site Web de FibroGen.
FibroGen (NASDAQ: FGEN) hat die Bekanntgabe seiner Finanzergebnisse für das dritte Quartal 2024 für Dienstag, den 12. November, nach Börsenschluss eingeplant. Das Unternehmen wird um 17:00 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Unternehmens- und Finanzleistung mit der Investorengemeinde zu besprechen. Die Konferenz ist über die gebührenfreie Nummer 1-877-300-8521 für nationale Anrufer und 1-412-317-6026 für internationale Investoren erreichbar. Eine Aufzeichnung des Webcasts wird im Investorenbereich von FibroGens Website verfügbar sein.
- None.
- None.
SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast
Toll-free: 1-877-300-8521
International investors: 1-412-317-6026
Webcast: Click here
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. A replay of the webcast will also be available for a limited time on the “Events and Presentation” page under the Investors section on the FibroGen website.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET biomarker, FG-3180. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com.
For Investor Inquiries:
David DeLucia, CFA
Vice President of Corporate FP&A / Investor Relations
InvestorRelations@fibrogen.com
FAQ
When will FibroGen (FGEN) release Q3 2024 earnings?
What time is FibroGen's (FGEN) Q3 2024 earnings call?
How can investors access FibroGen's (FGEN) Q3 2024 earnings call?
